Mirna Therapeutics Inc. (MIRN) Rating Reiterated by Leerink Swann
Mirna Therapeutics Inc. (NASDAQ:MIRN)‘s stock had its “neutral” rating reissued by Leerink Swann in a note issued to investors on Wednesday.
The analysts wrote, “We maintain our Market Perform rating for Amgen along with our $193 price target.””
A number of other equities analysts have also recently commented on MIRN. Zacks Investment Research raised shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price target for the company in a research note on Thursday, July 14th. Citigroup Inc. cut shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $7.00 to $4.50 in a research note on Tuesday, August 16th. Oppenheimer Holdings Inc. lifted their price target on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 16th. HC Wainwright started coverage on shares of Mirna Therapeutics in a research report on Monday, September 12th. They issued a “buy” rating and a $6.00 price objective for the company. Finally, Cantor Fitzgerald cut shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $6.96.
Shares of Mirna Therapeutics (NASDAQ:MIRN) opened at 1.96 on Wednesday. Mirna Therapeutics has a 12-month low of $1.82 and a 12-month high of $11.01. The stock’s 50 day moving average is $3.05 and its 200-day moving average is $4.08. The stock’s market cap is $40.84 million.
About Mirna Therapeutics
Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.
Receive News & Ratings for Mirna Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.